Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents

Current Medicinal Chemistry

Volumn 18, Issue 29, 2011, Pages 4418-4439

  Kourounakis, A P ^a   Katselou, M G ^a   Matralis, A N ^a   Ladopoulou, E M ^a   Bavavea, E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anti dyslipidemic; Antibiotics; Atherosclerosis; Benzoxazepines; Cholesterol biosynthesis; Hyperlipidemia; In vitro; In vivo; Lapaquistat; LDL; Morpholines; Quinuclidines; Squalestatins; Triglycerides

Indexed keywords

1ALPHA,2BETA BIS[[N PROPYL N (4 PHENOXYBENZYL)AMINO]CARBONYL] 3BETA,4ALPHA CYCLOBUTANEDICARBOXYLIC ACID; 2,8 DIOXABICYCLO[3.2.1]OCTANE DERIVATIVE; 4,1 BENZOXAZEPINE; BICYCLO[3.2.1]OCTANE DERIVATIVE; DICARBOXYLIC ACID; EP 2302; EP 2306; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; J 104118; J 104123; L 731120; LAPAQUISTAT; MEVINOLIN; MORPHOLINE DERIVATIVE; PRAVASTATIN; PROPYLAMINE; QUINUCLIDINE DERIVATIVE; RPR 107393; SQUALENE; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; SQUALESTATIN; UNCLASSIFIED DRUG; YM 53601; YM 75440; ZARAGOZIC ACID A; ZM 97480;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ATHEROSCLEROSIS; DRUG DISCOVERY; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS;

EID: 80053024735     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797287557     Document Type: Review

References (156)

1. Tyroler, H. A. Coronary heart disease epidemiology in the 21st century. Epidemiol. Rev., 2000, 22, 7-13. (Pubitemid 30627519)
2. Backer, G. G. D. The global burden of coronary heart disease. Medicographia, 2009, 31, 343-348.
3. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T. B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'Donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2009, 119, e21-181.
4. Catapano, A. L.; Maggi, F. M.; Tragni, E. Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Curr. Opin. Cardiol., 2000, 15, 355-363.
5. Asmis, R.; Begley, J. G.; Jelk, J.; Everson, W. V. Lipoprotein aggregation protects human monocyte-derived macrophages from OxLDL-induced cytotoxicity. J. Lipid Res., 2005, 46, 1124-1132. (Pubitemid 43109828)
6. Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Witztum, J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med., 1989, 320, 915-924. (Pubitemid 19101597)
7. Lehr, H. A.; Frei, B.; Olofsson, A. M.; Carew, T. E.; Arfors, K. E. Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E. Circulation, 1995, 91, 1525-1532.
8. Tavridou, A.; Manolopoulos, V. G. Novel molecules targeting dyslipidemia and atherosclerosis. Curr. Med. Chem., 2008, 15, 792-802. (Pubitemid 351516796)
9. Kunsch, C.; Medford, R. M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res., 1999, 85, 753-766. (Pubitemid 29480816)
10. Ross, R. Atherosclerosis is an inflammatory disease. Am. Heart. J., 1999, 138, S419-20. (Pubitemid 29523224)
11. Tiwari, A. Current and emerging paradigms in the therapeutic management of atherosclerosis. Expert Opin. Ther. Targets, 2008, 12, 1523-1546.
12. Montecucco, F.; Mach, F. Atherosclerosis is an inflammatory disease. Semin. Immunopathol., 2009, 31, 1-3.
13. Meng, C. Q. A new era in atherosclerosis drug discovery. Expert Rev. Cardiovasc. Ther., 2004, 2, 633-636. (Pubitemid 39255527)
14. Smith, S. C.; Allen, J.; Blair, S. N.; Bonow, R. O.; Brass, L. M.; Fonarow, G. C.; Grundy, S. M.; Hiratzka, L.; Jones, D.; Krumholz, H. M.; Mosca, L.; Pasternak, R. C.; Pearson, T.; Pfeffer, M. A.; Taubert, K. A. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation, 2006, 113, 2363-2372. (Pubitemid 43947981)
15. Davidson, M. Squalene Synthase Inhibition: A Novel Target for the Management of Dyslipidemia. Curr. Atheroscler. Rep., 2007, 9, 78-80. (Pubitemid 46075742)
16. Sacks, F. M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiol., 2002, 90, 139-143. (Pubitemid 34775122)
17. Chapman, M. J.; Assmann, G.; Fruchart, J. C.; Shepherd, J.; Sirtori, C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr. Med. Res. Opin., 2004, 20, 1253-1268. (Pubitemid 39120790)
18. Wierzbicki, A. S. New lipid-lowering agents. Expert Opin. Emerg. Drugs, 2003, 8, 365-376. (Pubitemid 37522656)
19. Wierzbicki, A. S. Lipid-altering agents: the future. Int. J. Clin. Pract., 2004, 58, 1063-1072. (Pubitemid 39642422)
20. Nachimuthu, S.; Raggi, P. Novel agents to manage dyslipidemias and impact atherosclerosis. Cardiovasc. Haemotol. Disord. Drug Targets, 2006, 6, 209-217. (Pubitemid 44377773)
21. Tardif, J. C. Antioxidants and atherosclerosis: emerging drug therapies. Curr. Atheroscler. Rep., 2005, 7, 71-77.
22. Stocker, R. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. Curr. Opin. Lipidol., 2009, 20, 227-235.
23. Muldrew, K. M.; Franks, A. M. Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects. Expert Opin. Investig. Drugs., 2009, 18, 531-539.
24. Goldberg, A. C. Novel therapies and new targets of treatment for familial hypercholesterolemia. J. Clin. Lipidol., 2010, 4, 350-356. Epub 2010 Aug 21.
25. Berg, J. M.; Tymoczko, J. L.; Stryer, L. Biochemistry, 5th edition. New York: W. H. Freeman, 2002.
26. Biller S. A.; Neuenschwander K.; Ponpipom M. M.; Poulter D. C. Squalene synthase inhibitors. Current Pharmaceutical Design 1996, 2, 1-40. (Pubitemid 126637694)
27. Menys, V. C.; Durrington, P. N. Squalene Synthase Inhibitors. British Journal of Pharmacology 2003, 139, 881-882. (Pubitemid 36877385)
28. Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2, 517-526. (Pubitemid 37361744)
29. Endo, A. A historical perspective on the discovery of statins. Proc., 2010, 86, 484-493.
30. Halcox, J. P.; Deanfield, J. E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 2004, 109, II42-48. (Pubitemid 38724155)
31. Charlton-Menys V, D. P. Squalene Synthase Inhibitors: Clinical Pharmacology and Cholesterol-Lowering Potential. Drugs, 2007, 67, 11-16.
32. Sliskovic, D.; Picard, J. A. A Squalene synthase inhibitors. Emerging Drugs, 1997, 2, 93-107.
33. Edwards, P. A.; Ericsson, J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem., 1999, 68, 157-185. (Pubitemid 29449190)
34. Eggens, I.; Eriksson, L. C.; Chojnacki, T.; Dallner, G. Role of dolichyl phosphate in regulation of protein glycosylation in 2-acetylaminofluoreneinduced carcinogenesis in rat liver. Cancer Res., 1984, 44, 799-805. (Pubitemid 14184621)
35. Wierzbicki, A. S. Lipid-lowering therapies in development. Expert Opin. Investig. Drugs, 2004, 13, 1405-1418. (Pubitemid 39530194)
36. Tansey, T. R.; Shechter, I. Structure and regulation of mammalian squalene synthase. Biochim. Biophys. Acta, 2000, 1529, 49-62.
37. Watson, N. S.; Procopiou, P. A. Squalene synthase inhibitors: their potential as hypocholesterolaemic agents. Prog. Med. Chem., 1996, 33, 331-378.
38. Rosemberg, S. H. Squalene synthase inhibitors 1998. Exp. Opin. Ther. Patents, 1998, 8, 521-530.
39. Sasiak, K.; Rilling, H. C. Purification to homogeneity and some properties of squalene synthetase. Arch. Biochem. Biophys., 1988, 260, 622-627.
40. Pandit, J.; Danley, D. E.; Schulte, G. K.; Mazzalupo, S.; Pauly, T. A.; Hayward, C. M.; Hamanaka, E. S.; Thompson, J. F.; Harwood, H. J., Jr. Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis. J. Biol. Chem., 2000, 275, 30610-30617.
41. Rilling, H. C.; Chayet, L. T. Biosynthesis of cholesterol. In: Sterols and Bile Acids. Danielson H., Sjovall J. (Eds) Elsevier, Amsterdam, 1985, 1-72.
42. Gibbons, G. F.; Mitropoulos, K. A; Myant, N. B. Biochemistry of cholesterol. Amsterdam: Elsevier Biomediacl. Press, 1982, 131-188.
43. Ness, G. C.; Zhao, Z.; Keller, R. K. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase. Arch. Biochem. Biophys., 1994, 311, 277-285.
44. Hiyoshi, H.; Yanagimachi, M.; Ito, M.; Saeki, T.; Yoshida, I.; Okada, T.; Ikuta, H.; Shinmyo, D.; Tanaka, K.; Kurusu, N.; Tanaka, H. Squalene syn thase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur. J. Pharmacol., 2001, 431, 345-352. (Pubitemid 33145413)
45. Hiyoshi, H.; Yanagimachi, M.; Ito, M.; Ohtsuka, I.; Yoshida, I.; Saeki, T.; Tanaka, H. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3- methylglutaryl-coa reductase inhibitors. J. Lipid Res., 2000, 41, 1136-1144. (Pubitemid 30483019)
46. Hiyoshi, H.; Yanagimachi, M.; Ito, M.; Yasuda, N.; Okada, T.; Ikuta, H.; Shinmyo, D.; Tanaka, K.; Kurusu, N.; Yoshida, I.; Abe, S.; Saeki, T.; Tanaka, H. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J. Lipid Res., 2003, 44, 128-135. (Pubitemid 36114778)
47. Bradfute, D. L.; Simoni, R. D. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J. Biol. Chem., 1994, 269, 6645-6650.
48. Correll, C. C.; Ng, L.; Edwards, P. A. Identification of farnesol as the nonsterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem., 1994, 269, 17390-17393.
49. Meigs, T. E.; Roseman, D. S.; Simoni, R. D. Regulation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem., 1996, 271, 7916-7922. (Pubitemid 26108608)
50. Meigs, T. E.; Simoni, R. D. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys., 1997, 345, 1-9. (Pubitemid 27374202)
51. Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.; Perlmann, T.; Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W. W.; Evans, R. M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81, 687-693.
52. Hanley, K.; Komuves, L. G.; Ng, D. C.; Schoonjans, K.; He, S. S.; Lau, P.; Bikle, D. D.; Williams, M. L.; Elias, P. M.; Auwerx, J.; Feingold, K. R. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J. Biol. Chem., 2000, 275, 11484-11491. (Pubitemid 30212804)
53. Bertolino, A.; Altman, L. J.; Vasak, J.; Rilling, H. C. Polyisoprenoid amphiphilic compounds as inhibitors of squalene synthesis and other microsomal enzymes. Biochim. Biophys. Acta, 1978, 530, 17-23. (Pubitemid 8401252)
54. Biller, S. A.; Forster, C.; Gordon, E. M.; Harrity, T.; Rich, L. C.; Marretta, J.; Ciosek, C. P., Jr. Isoprenyl phosphinylformates: new inhibitors of squalene synthetase. J. Med. Chem., 1991, 34, 1912-1914.
55. Biller, S. A.; Sofia M. J.; DeLange, B.; Forster, C.; Gordon, E. M.; Harrity, T.; Rich, L. C.; Ciosek, C. P., Jr. The first potent inhibitor of squalene synthase: A profound contribution of an ether oxygen to inhibitoe-enzyme interaction. J. Am. Chem. Soc., 1991, 113, 8522-8524.
56. Biller, S. A.; Abt, J. W.; Pudzianowski, A. T.; Rich, L. C.; Slusarchyk, D. A.; Ciosek, C. P., Jr. Aromatic Isosters As Conformational Probes For An Isoprenyl Subunit: Application To Inhibitors of Squalene Synthase. Bioorg. Med. Chem. Letters, 1993, 3, 595-600. (Pubitemid 23109573)
57. Kalinowski, S. S.; Mookhtiar, K. A. Mechanism of inhibition of yeast squalene synthase by substrate analog inhibitors. Arch. Biochem. Biophys., 1999, 368, 338-346. (Pubitemid 29406559)
58. Amin, D.; Cornell, S. A.; Gustafson, S. K.; Needle, S. J.; Ullrich, J. W.; Bilder, G. E.; Perrone, M. H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res., 1992, 33, 1657-1663.
59. Magnin, D. R.; Biller, S. A.; Chen, Y.; Dickson, J. K., Jr.; Fryszman, O. M.; Lawrence, R. M.; Logan, J. V.; Sieber-McMaster, E. S.; Sulsky, R. B.; Traeger, S. C.; Hsieh, D. C.; Lan, S. J.; Rinehart, J. K.; Harrity, T. W.; Jolibois, K. G.; Kunselman, L. K.; Rich, L. C.; Slusarchyk, D. A.; Ciosek, C. P., Jr. alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J. Med. Chem., 1996, 39, 657-660. (Pubitemid 26069686)
60. Ciosek, C. P., Jr.; Magnin, D. R.; Harrity, T. W.; Logan, J. V.; Dickson, J. K., Jr.; Gordon, E. M.; Hamilton, K. A.; Jolibois, K. G.; Kunselman, L. K.; Lawrence, R. M.; et al. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem., 1993, 268, 24832-24837. (Pubitemid 23335498)
61. Magnin, D. R.; Biller, S. A.; Dickson, J. K., Jr.; Logan, J. V.; Lawrence, R. M.; Chen, Y.; Sulsky, R. B.; Ciosek, C. P., Jr.; Harrity, T. W.; Jolibois, K. G.; et al. 1,1-Bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J. Med. Chem., 1995, 38, 2596-2605.
62. Dickson, J. K., Jr.; Biller, S. A.; Magnin, D. R.; Petrillo, E. W., Jr.; Hillyer, J. W.; Hsieh, D. C.; Lan, S. J.; Rinehart, J. K.; Gregg, R. E.; Harrity, T. W.; Jolibois, K. G.; Kalinowski, S. S.; Kunselman, L. K.; Mookhtiar, K. A.; Ciosek, C. P., Jr. Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. J. Med. Chem., 1996, 39, 661-664. (Pubitemid 26069687)
63. Lawrence R. M.; Biller, S. A.; Dickson, J. K., Jr; Logan, J. V. H.; Magnin, D. R.; Sulsky, R. B.; DiMarco, J. D.; Gougoutas, J. Z.; Beyer, B. D.; Taylor, S. C.; Lan, S.-J.; Ciosek, C. P., Jr; Harrity, T. W.; Jolibois, K. G.; Kunselman, L. K.; Slusarchyk, D. A. Enantioselective synthesis of α-phosphono sulfonate squalene synthase inhibitors: Chiral recognition in the interactions of an α-phosphono sulfonate inhibitor with squalene synthase. J. Am. Chem. Soc., 1996, 118, 11668-11669. (Pubitemid 26399704)
64. Wattanasin, S.; Boettcher, B. R.; Scallen, T. N-Hydroxyglycine derivatives as novel inhibitors of squalene synthase. Bioorg. Med. Chem. Letters, 1997, 7, 3039-3044. (Pubitemid 27519581)
65. Poulter, C. D.; Capson, T. L.; Thompson, M. D. and Bard, R. S. Squalene synthetase. Inhibition by ammonium analogues of carbocationic intermediates in the conversion of presqualene diphosphate to squalene. J. Am. Chem. Soc., 1989, 111, 3734-3739.
66. Steiger, A.; Hyung-Jung, P.; Coates, R. Synthesis and Characterization of Aza Analogue Inhibitors of Squalene and Geranylgeranyl Diphosphate Synthases. J. Org. Chem., 1992, 57.
67. Oehlschlager, A. C.; Singh, S. M.; Sharma, S. Squalene synthetase inhibitors: synthesis of sulfonium ion mimics of the carbocationic intermediates. J. Org. Chem. 1991, 56, 3856-3861.
68. Prashad, M.; Kathawala, F. G.; Scallen, T. N-(arylalkyl)farnesylamines: new potent squalene synthetase inhibitors. J. Med. Chem., 1993, 36, 1501-1504. (Pubitemid 23164510)
69. Brinkman, J. A.; Damon, R. E.; Fell, J. B.; Perez, L. B. Squalene Synthase Inhibitors: Isosteric Replacements of the Farnesyl Chain of Benzyl Farnesyl Amine. Bioorg. Med. Chem. Letters, 1996, 6, 2491-2494. (Pubitemid 26375257)
70. Ullrich, J. W.; Kiesow, T. J.; Neuenschwander, K. W.; Scotese, A. C.; Learn, K. S.; Dankulich, W.P. Patent Appl., WO 9414435 1994.
71. Rutledge, R.; Needle, S.; Galczenski, H; Bush, R.; Hele, D.; Rojas, C.; Ullrich, J.; Neuenschwander, K.; Bilder, G.; Perrone, M.; Amin, D. A mechanism of cholesterol-lowering effect of RPR 101821: Inhibition of squalene synthase and 7-dehydrocholesterol reductase. FASEB J.. 1995, 9, A195.
72. Morris, R. L.; Neuenschwander, K. W.; Learn, K. S.; Scotese, A. C. Patent Appl., WO 9500146 1995.
73. Morris, R. L.; Neuenschwander, K. W.; Learn, K. S.; Scotese, A. C. US Patent Appl., 5 395 846 1995.
74. Koohang, A.; Coates R. M. Synthesis and evaluation of aziridine analogues of presqualene diphosphate as squalene synthase inhibitors. J. Org. Chem., 1999, 64, 6-7. (Pubitemid 29037297)
75. Koohang, A.; Bailey, J. L.; Coates, R. M.; Erickson, H. K.; Owen, D.; Poulter, C. D. Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. J. Org. Chem., 2010, 75, 4769-4777.
76. Bergstrom, J. D.; Kurtz, M. M.; Rew, D. J.; Amend, A. M.; Karkas, J. D.; Bostedor, R. G.; Bansal, V. S.; Dufresne, C.; VanMiddlesworth, F. L.; Hensens, O. D.; et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 80-84. (Pubitemid 23010253)
77. Shu, Y-Z. Recent Natural Products Based Drug Development: A Pharmaceutical Industry Perspective. J. Nat. Prod., 1998, 61, 1053-1071. (Pubitemid 28417273)
78. Baxter, A.; Fitzgerald, B. J.; Hutson, J. L.; McCarthy, A. D.; Motteram, J. M.; Ross, B. C.; Sapra, M.; Snowden, M. A.; Watson, N. S.; Williams, R. J.; et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem., 1992, 267, 11705-11708.
79. Lindsey S.; Harwood, H. J. J. Inhibition of Mammalian Squalene Synthetase Activity by Zaragozic Acid A Is a Result of Competitive Inhibition Followed by Mechanism-based Irreversible Inactivation. J. Biol. Chem., 1994, 270, 9083-9096.
80. Procopiou, P. A.; Bailey, E. J.; Bamford, M. J.; Craven, A. P.; Dymock, B. W.; Houston, J. G.; Hutson, J. L.; Kirk, B. E.; McCarthy, A. D.; Sareen, M.; et al. The squalestatins: novel inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C1-modified analogues. J. Med. Chem., 1994, 37, 3274-3281. (Pubitemid 24325040)
81. Chan, C.; Andreotti, D.; Cox, B.; Dymock, B. W.; Hutson, J. L.; Keeling, S. E.; McCarthy, A. D.; Procopiou, P. A.; Ross, B. C.; Sareen, M.; Scicinski, J. J.; Sharratt, P. J.; Snowden, M. A.; Watson, N. S. The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors. J. Med. Chem., 1996, 39, 207-216. (Pubitemid 26023514)
82. Sharratt P. J.; Hutson, J. L.; Inglis G. G. A.; Lester M. G.; Procopiou P. A.; Watson N. S. Structurally simplified Squalestatins: monocyclic 1,3-dioxane analogues. Bioorg. Med. Chem. Lett., 1994, 4, 661-666. (Pubitemid 24101755)
83. Harris, G. H.; Dufresne, C.; Joshua, H.; Koch, L. A.; Zink, D. L.; Salmon, P. M.; G6klen, K. E.; Kurtz, M. M.; Rew, D. J.; Bergstrom, J. D.; Wilson, K. E. Isolation, Structure Determination and Squalene Synthase Activity of L-731,120 and L-731,128, Alkyl Citrate Analogs of Zaragozic Acids A and B. Bioorg. Med. Chem. Lett., 1995, 5, 2403-2408.
84. Nadin, A.; Nicolaou, K.C. Chemistry and Biology of the Zaragozic Acids (Squalestatins). Angew. Chem. Int. Ed. Engl., 1996, 35, 1622-1656.
85. Keller, R. K. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim. Biophys. Acta, 1996, 1303, 169-179. (Pubitemid 26349035)
86. Bostedor, R. G.; Karkas, J. D.; Arison, B. H.; Bansal, V. S.; Vaidya, S.; Germershausen, J. I.; Kurtz, M. M.; Bergstrom, J. D. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J. Biol. Chem., 1997, 272, 9197-9203. (Pubitemid 27154927)
87. Vaidya, S.; Bostedor, R.; Kurtz, M. M.; Bergstrom, J. D.; Bansal, V. S. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys., 1998, 355, 84-92. (Pubitemid 28371155)
88. Tanimoto, T.; Tsujita, Y.; Hamano, K.; Haruyama, H.; Kinoshita, T.; Hosoya, T.; Kaneko, S.; Tago, K.; Kogen, H. Schizostatin, a potent squalene synthase inhibitor from Schizophyllum commune: Isolation, structure elucidation and total synthesis. Tetrahedron Lett., 1995, 36, 6301-6304.
89. Iwasawa, Y.; Hayashi, M.; Nomoto, T.; Shibata, J.; Mitsuya, M.; Hirota, K.; Yonemoto, M.; Kamei, T.; Miura, K.; Tomimoto, K. Synthesis and Biological Activity of J-104,118, A Novel, Potent Inhibitor of Squalene Synthase. Bioorg. Med. Chem. Lett., 1995, 5, 1989-1994.
90. lwasawa, Y.; Shibata, J.; Mitsuya, M.; Masaki, H.; Hayashi, M.; Kanno, T.; Sawasaki, Y.; Hisaka, A.; Kamei, T.; Tomimoto, K. J-104,123, A Novel and Orally-active Inhibitor of Squalene Synthase: Stereoselective Synthesis and Cholesterol Lowering Effects in Dogs. Bioorg. Med. Chem. Lett., 1996, 6, 463-466. (Pubitemid 26081813)
91. Fung, A. K.; Baker, W. R.; Fakhoury, S.; Stein, H. H.; Cohen, J.; Donner, B. G.; Garvey, D. S.; Spina, K. P.; Rosenberg, S. H. (1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4- dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor. J. Med. Chem., 1997, 40, 2123-2125. (Pubitemid 27284348)
92. Shen, W.; Garvey, D. S.; Cohen, J.; Stein, H.; Rosenberg, S. H. Cyclopentanedi- and tricarboxylic acids as squalene synthase inhibitors: synthesis and evaluation. Bioorg. Med. Chem. Lett., 1998, 8, 891-896. (Pubitemid 28206598)
93. Brown, G. R.; Butlin, R. J.; Chapman, S.; Eakin, M. A.; Foubister, A. J.; Freeman, S.; Griffiths, D.; Harrison, P. J.; Johnson, M. C.; Mallion, K. B.; et al. Phenoxypropylamines: a new series of squalene synthase inhibitors. J. Med. Chem., 1995, 38, 4157-4160.
94. Ishihara, T.; Kakuta, H.; Moritani, H.; Ugawa, T.; Yanagisawa, I. Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg. Med. Chem., 2004, 12, 5899-5908. (Pubitemid 39388189)
95. Brown, G. R.; Clarke, D. S.; Foubister, A. J.; Freeman, S.; Harrison, P. J.; Johnson, M. C.; Mallion, K. B.; McCormick, J.; McTaggart, F.; Reid, A. C.; Smith, G. J.; Taylor, M. J. Synthesis and activity of a novel series of 3- biarylquinuclidine squalene synthase inhibitors. J. Med. Chem., 1996, 39, 2971-2979. (Pubitemid 26251035)
96. McTaggart, F.; Brown, G. R.; Davidson, R. G.; Freeman, S.; Holdgate, G. A.; Mallion, K. B.; Mirrlees, D. J.; Smith, G. J.; Ward, W. H. Inhibition of squalene synthase of rat liver by novel 3' substituted quinuclidines. Biochem. Pharmacol., 1996, 51, 1477-1487.
97. Ward, W. H. J.; Holdgate G. A.; Freeman, S.; McTaggart, F.; Girdwood, P. A.; Davidson, R. G.; Mallion, K. B.; Brown, G. R.; Eakin A. Inhibition of Squalene Synthase In vitro by 3-(Biphenyl4-yl)-Quinuclidine. Biochem. Pharmacol., 1996, 51, 1489-1501.
98. Brown, G. R.; Foubister, A. J.; Freeman, S.; McTaggart, F.; Mirrlees, D. J.; Reid, A. C.; Smith, G. J.; Taylor, M. J.; Thomason, D. A.; Whittamore, P. R. O. Novel optimised quinuclidine squalene synthase inhibitors. Bioorg. Med. Chem. Letters 1997, 7, 597-600. (Pubitemid 27093075)
99. Amin, D.; Rutledge, R. Z.; Needle, S. N.; Galczenski, H. F.; Neuenschwander, K.; Scotese, A. C.; Maguire, M. P.; Bush, R. C.; Hele, D. J.; Bilder, G. E.; Perrone, M. H. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther., 1997, 281, 746-752. (Pubitemid 27203807)
100. Ishihara, T.; Kakuta, H.; Moritani, H.; Ugawa, T.; Sakamoto, S.; Tsukamoto, S.; Yanagisawa, I. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg. Med. Chem., 2003, 11, 2403-2414. (Pubitemid 36539376)
101. Ishihara, T.; Kakuta, H.; Moritani, H.; Ugawa, T.; Sakamoto S.; Tsukamoto, S. I.; Yanagisawa, I. Syntheses of 3-Ethylidenequinuclidine Derivatives as Squalene Synthase Inhibitors. Part 2: Enzyme Inhibition and Effects on Plasma Lipid Levels. Bioorg. Med. Chem., 2003, 11, 3735-3745. (Pubitemid 36952271)
102. Ishihara, T.; Kakuta, H.; Moritani, H.; Ugawa, T.; Yanagisawa, I. Synthesis and Biological Evaluation of Quinuclidine Derivatives Incorporating Phenothiazine Moieties as Squalene Synthase Inhibitors. Chem. Pharm. Bull., 2004, 52, 1204-1209. (Pubitemid 41327513)
103. Ugawa, T.; Kakuta, H.; Moritani, H.; Matsuda, K.; Ishihara, T.; Yamaguchi, M.; Naganuma, S.; Iizumi, Y.; Shikama, H. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol., 2000, 131, 63-70.
104. Ugawa, T.; Kakuta, H.; Moritani, H.; Inagaki, O.; Shikama, H. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br. J. Pharmacol., 2003, 139, 140-146. (Pubitemid 36645317)
105. Brown, G. R.; Hollinshead, D. M.; Stokes, E. S.; Clarke, D. S.; Eakin, M. A.; Foubister, A. J.; Glossop, S. C.; Griffiths, D.; Johnson, M. C.; McTaggart, F.; Mirrlees, D. J.; Smith, G. J.; Wood, R. Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles. J. Med. Chem., 1999, 42, 1306-1311. (Pubitemid 29181152)
106. Fairlamb, I. J.; Dickinson, J. M.; O'Connor, R.; Higson, S.; Grieveson, L.; Marin, V. Identification of novel mammalian squalene synthase inhibitors using a three-dimensional pharmacophore. Bioorg. Med. Chem., 2002, 10, 2641-2656. (Pubitemid 34626227)
107. Miki, T.; Kori, M.; Fujishima, A.; Mabuchi, H.; Tozawa, R.; Nakamura, M.; Sugiyama, Y.; Yukimasa, H. Syntheses of fused heterocyclic compounds and their inhibitory activities for squalene synthase. Bioorg. Med. Chem., 2002, 10, 385-400. (Pubitemid 33121263)
108. Miki, T.; Kori, M.; Mabuchi, H.; Banno, H.; Tozawa, R.; Nakamura, M.; Itokawa, S.; Sugiyama, Y.; Yukimasa, H. Novel 1,4-Benzoxazepin derivatives with potent squalene synthase inhibitory activities. Bioorg. Med. Chem., 2002, 10, 401-414. (Pubitemid 33121264)
109. Miki, T.; Kori, M.; Tozawa, R.; Nakamura, M.; Sugiyama, Y.; Yukimasa, H. Syntheses of (4,1-Benzoxazepine-3-ylidene)acetic acid derivatives and their inhibition of squalene synthase. Chem. Pharm. Bull., 2002, 50, 53-58. (Pubitemid 44724579)
110. Miki, T.; Kori, M.; Mabuchi, H.; Tozawa, R.; Nishimoto, T.; Sugiyama, Y.; Teshima, K.; Yukimasa, H. Synthesis of novel 4,1-Benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J. Med. Chem., 2002, 45, 4571-4580.
111. Amano, Y.; Nishimoto, T.; Tozawa, R.; Ishikawa, E.; Imura, Y.; Sugiyama, Y. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur. J. Pharmacol., 2003, 466, 155-161. (Pubitemid 36385101)
112. Nishimoto, T.; Amano, Y.; Tozawa, R.; Ishikawa, E.; Imura, Y.; Yukimasa, H.; Sugiyama, Y. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br. J. Pharmacol., 2003, 139, 911-918. (Pubitemid 36877390)
113. Flint, O. P.; Masters, B. A.; Gregg, R. E.; Durham, S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol., 1997, 145(1), 91-98. (Pubitemid 27294774)
114. (a)Nishimoto, T.; Tozawa, R.; Amano, Y.; Wada, T.; Imura, Y.; Sugiyama, Y. Comparing Myotoxic Effects of Squalene Synthase Inhibitor, T-91485, and 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-COA) Reductase Inhibitors In Human Myocytes. Biochem. Pharmacol., 2003, 66, 2133-2139. (Pubitemid 37377859)
115. (b)Nishimoto, T.; Ishikawa, E.; Anayama, H.; Hamajyo, H.; Nagai, H.; irakata, M.; Tozawa, R. Protective effects of a squalene synthase inhibitor, apaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. oxicol. Appl. Pharmacol., 2007, 223(1), 39-45. (Pubitemid 47211267)
116. (a)El Harchaoui, K.; Akdim, F.; Stroes, E. S.; Trip, M. D.; Kastelein, J. J. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins. Am. J. Cardiovasc. Drugs, 2008, 8, 233-242.
117. (b)Davidson, M. H. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr. Atheroscler. Rep., 2009, 11, 67-70.
118. Shiomi, M.; Yamada, S.; Amano, Y.; Nishimoto, T.; Ito, T. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br. J. Pharmacol., 2008, 154, 949-57. (Pubitemid 351915051)
119. Burnett, J. R. Drug evaluation: TAK-475-an oral inhibitor of squalene synthase for hyperlipidemia. Curr. Opin. Investig. Drugs, 2006, 7, 850-856. (Pubitemid 44382792)
120. Davidson, M. H.; Maci, K. C.; Zavoral, J. H.; Yu, S.; Popovici, C.; Price, G. D. Lapaquistat Acetate, A Novel Squalene Synthase Inhibitor, Coadministered with Atorvastatin Reduces Plasma Lipids and C-Reactive Protein Levels in Subjects with Primary Hypercholesterolemia. Circulation, 2007.
121. Elsayed, R. K.; Evans, J. D. Emerging lipid-lowering drugs: squalene synthase inhibitors. Expert Opin. Emerg. Drugs, 2008, 13, 309-322. (Pubitemid 351957350)
122. (a)Stein, E. A.; Bays, H.; O' Brien, D.; Pedicano, J.; Piper, E.; Spezzi, A. Lapaquistat Acetate. Development of a Squalene Synthase Inhibitor for the Treatment of Hypercholesterolemia. Circulation, 2011, 123, 1974-1985.
123. (b) Takeda. Discontinuation of Development of TAK-475, a Compound for Treatment of Hypercholesterolemia. Press release March 2008 online. [URL: http:/www.takeda.com/press/article 29153.html].
124. Rekka, E. A.; Kourounakis, P. N. Medicinal chemistry of 2,2,4-substituted morpholines. Curr. Med. Chem., 2010, 17, 3422-3430.
125. Chrysselis, M. C.; Rekka, E. A.; Kourounakis, P. N. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J. Med. Chem., 2000, 43, 609-612. (Pubitemid 30127156)
126. Rekka, E. A.; Kourounakis, A. P.; kourounakis, P. N. Rational Drug Design Based Mainly on the Pathobiochemistry of the Disease: Examples of Atheromatosis and Alzheimer's Type Neurodegeneration. CRC Press, Taylor & Francis Group, Editors: E. A. Rekka, P. N. Kourounakis. 2008.
127. Chrysselis, M. C.; Rekka, E. A.; Siskou, I. C.; Kourounakis, P. N. Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J. Med. Chem., 2002, 45, 5406-5409. (Pubitemid 35429179)
128. Tavridou, A.; Manolopoulos, V. G. Antioxidant properties of two novel 2- biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. Eur. J. Pharmacol., 2004, 505, 213-221. (Pubitemid 39535694)
129. Kurowska, E. M.; Carroll, K. K. Hypocholesterolemic properties of nitric oxide. In vivo and in vitro studies using nitric oxide donors. Biochim. Biophys. Acta, 1998, 1392, 41-50. (Pubitemid 28291850)
130. Tavridou, A.; Kaklamanis, L.; Megaritis, G.; Kourounakis, A. P.; Papalois, A.; Roukounas, D.; Rekka, E. A.; Kourounakis, P. N.; Charalambous, A.; Manolopoulos, V. G. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur. J. Pharmacol., 2006, 535, 34-42.
131. Rekka, E. A.; Kourounakis, A. P.; Avramidis, N.; Kourounakis, P. N. Effect of Some Biollogically Interesting Substituted Tetrahydro-1,4-Oxazines On Drug Metabolising Enzymes and on Inflammation. Current Drug Metabolism 2005, 6, 481-485. (Pubitemid 41300792)
132. Tavridou, A.; Megaritis, G.; Kourounakis, A. P.; Charalambous, A.; Manolopoulos, V. G. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium, 2007, 14, 239-243. (Pubitemid 47543010)
133. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A. P.; Rekka, E. A.; Kourounakis, P. N.; Charalambous, A.; Manolopoulos, V. G. EP2306 [2- (4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterolfed rabbit. J. Pharmacol. Exp. Ther., 2007, 323, 794-804. (Pubitemid 350146049)
134. Roy, K.; Mitra, I.; Saha, A. Molecular shape analysis of antioxidant and squalene synthase inhibitory activities of aromatic tetrahydro-1,4-oxazine derivatives. Chem. Biol. Drug Des., 2009, 74, 507-516.
135. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A. P.; Rekka, E. A.; Kourounakis, P. N.; Charalambous, A.; Manolopoulos, V. G. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor,
136. Tavridou, A.; Manolopoulos, V. G. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. Curr. Pharm. Des., 2009, 15, 3167-3178.
137. Kourounakis, A. P.; Charitos, C.; Rekka, E. A.; Kourounakis, P. N. Lipidlowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J. Med. Chem., 2008, 51, 5861-5865.
138. Nikitakis, A.; Kourounakis A.P. QSAR of substituted morpholines with antioxidant and squalene synthase activity. Med. Chem. Res., 2010.
139. Kourounakis, A. P.; Matralis, A. N.; Nikitakis, A. Design of more potent squalene synthase inhibitors with multiple activities. Bioorg. Med. Chem., 2010, 18, 7402-7412.
140. Urbina, J. A.; Concepcion, J. L.; Rangel, S.; Visbal, G.; Lira, R. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol., 2002, 125, 35-45. (Pubitemid 35449244)
141. Orenes Lorente, S.; Gomez, R.; Jimenez, C.; Cammerer, S.; Yardley, V.; de Luca-Fradley, K.; Croft, S. L.; Ruiz Perez, L. M.; Urbina, J.; Gonzalez Pacanowska, D.; Gilbert, I. H. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg. Med. Chem., 2005, 13, 3519-3529. (Pubitemid 40545807)
142. Urbina, J. A.; Concepcion, J. L.; Caldera, A.; Payares, G.; Sanoja, C.; Otomo, T.; Hiyoshi, H. In vitro and in vivo activities of E5700 and ER- 119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother., 2004, 48, 2379-2387. (Pubitemid 38823400)
143. Cammerer, S. B.; Jimenez, C.; Jones, S.; Gros, L.; Lorente, S. O.; Rodrigues, C.; Rodrigues, J. C.; Caldera, A.; Ruiz Perez, L. M.; da Souza, W.; Kaiser, M.; Brun, R.; Urbina, J. A.; Gonzalez Pacanowska, D.; Gilbert, I. H. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother., 2007, 51, 4049-4061. (Pubitemid 350063999)
144. Sealey-Cardona, M.; Cammerer, S.; Jones, S.; Ruiz-Perez, L. M.; Brun, R.; Gilbert, I. H.; Urbina, J. A.; Gonzalez-Pacanowska, D. Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob. Agents Chemother., 2007, 51, 2123-2129. (Pubitemid 46903104)
145. Ishida, K.; Visbal, G.; Rodrigues, J. C.; Urbina, J. A.; de Souza, W.; Rozental, S. Two squalene synthase inhibitors, E5700 and ER-119884, interfere with cellular proliferation and induce ultrastructural and lipid profile alterations in a Candida tropicalis strain resistant to fluconazole, itraconazole, and amphotericin B. J. Infect. Chemother., 2011.
146. Ishida, K.; Fernandes Rodrigues, J. C.; Cammerer, S.; Urbina, J. A.; Gilbert, I.; de Souza, W.; Rozental, S. Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis. Ann. Clin. Microbiol. Antimicrob., 2011, 10, 3.
147. Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridkin, S. K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA, 2007, 298, 1763-1771. (Pubitemid 47598444)
148. Bancroft, E. A. Antimicrobial resistance: it's not just for hospitals. JAMA, 2007, 298, 1803-1804. (Pubitemid 47598451)
149. Liu, C. I.; Liu, G. Y.; Song, Y.; Yin, F.; Hensler, M. E.; Jeng, W. Y.; Nizet, V.; Wang, A. H.; Oldfield, E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science, 2008, 319, 1391-1394. (Pubitemid 351354874)
150. Sharma, A.; Slugg, P. H.; Hammett, J. L.; Jusko, W. J. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm. Res., 1998, 15, 1782-1786. (Pubitemid 28524592)
151. Sharma, A.; Slugg, P. H.; Hammett, J. L.; Jusko, W. J. Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J. Clin. Pharmacol., 1998, 38, 1116-1121. (Pubitemid 29046594)
152. Linder, M. D.; Ikonen, E. Genetics and molecular biology: a cholesterollowering drug with antibacterial properties. Curr. Opin. Lipidol., 2008, 19, 324-325. (Pubitemid 351653571)
153. Oldfield, E. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc. Chem. Res., 2010, 43, 1216-1226.
154. Griebenow, N.; Flessner, T.; Buchmueller, A.; Raabe, M.; Bischoff, H.; Kolkhof, P. Identification and optimization of tetrahydro-2H-3-benzazepin-2-ones as squalene synthase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 2554-2558.
155. Ichikawa, M.; Yokomizo, A.; Itoh, M.; Sugita, K.; Usui, H.; Shimizu, H.; Suzuki, M.; Terayama, K.; Kanda, A. Discovery of a new 2-aminobenzhydrol template for highly potent squalene synthase inhibitors. Bioorg. Med. Chem., 2011, 19, 1930-1949.
156. Matralis, A. N.; Katselou, M. G.; Nikitakis, A.; Kourounakis , A. P. Novel Benzoxazine and Benzothiazine Derivatives as Multifunctional Antihyperlipidemic Agents. J. Med. Chem., 2011, 54, 5583-5591.